38 research outputs found

    Products from the high temperature pyrolysis of RDF at slow and rapid heating rates

    Get PDF
    The high-temperature pyrolysis behaviour of a sample of refuse derived fuel (RDF) as a model of municipal solid waste (MSW) was investigated in a horizontal tubular reactor between 700 and 900 °C, at varying heating rates, and at an extended vapour residence time. Experiments were designed to evaluate the influence of process conditions on gas yields as well as gas and oil compositions. Pyrolysis of RDF at 800 °C and at rapid heating rate resulted in the gas yield with the highest CV of 24.8 MJ m-3 while pyrolysis to 900 °C at the rapid heating rate generated the highest gas yield but with a lower CV of 21.3 MJ m-3. A comparison of the effect of heating rates on oil products revealed that the oil from slow pyrolysis, contained higher yields of more oxygenates, alkanes (C8-C39) and alkenes (C8-C20), while the oil from rapid pyrolysis contained more aromatics, possibly due to the promotion of Diels-Alder-type reactions

    Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models.

    Get PDF
    Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The NLRP3 inflammasome is a multi-protein complex responsible for the processing of the proinflammatory cytokine interleukin-1β and is implicated in many inflammatory diseases. Here we show that several clinically approved and widely used NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3 inflammasome via inhibition of the volume-regulated anion channel in macrophages, independently of COX enzymes. Flufenamic acid and mefenamic acid are efficacious in NLRP3-dependent rodent models of inflammation in air pouch and peritoneum. We also show therapeutic effects of fenamates using a model of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer's disease. These data suggest that fenamate NSAIDs could be repurposed as NLRP3 inflammasome inhibitors and Alzheimer's disease therapeutics

    Surfactant mixtures at interfaces

    No full text
    International audienc
    corecore